Nona Biosciences, a global biotechnology company providing a total solution from “Idea to IND” (I to ITM), ranging from target validation and antibody discovery through preclinical research, announced today that it has entered into a collaboration...
Gamma delta T cell-based immunotherapies have emerged as a promising frontier in cancer treatment and beyond, building on the success of chimeric antigen receptor T-cell (CAR T cell) therapy and expanding on the potential of the immune system as a therapeutic...
Will initiate a first-in-human Phase 1 clinical trial for INT2104, its first-in-class in vivo targeted gene therapy, creating CAR cells for the treatment of B cell malignancies in 4Q24 Interius BioTherapeutics, a leading developer of in vivo cell-specific gene...
Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company known for its innovative mRNA cell therapies targeting autoimmune diseases, announced today a significant milestone in its financial journey. The company has entered into a securities...
Stem cell research recently celebrated its 60th anniversary. Although the first publications in this field appeared in the early 1960s, it took another 20 years before the first embryonic stem cells could be isolated. Another important milestone was passed in 2006,...
